The phase II ATEMPT trial randomized women with HER2+ T1–2N0–N1mic breast cancer to adjuvant trastuzumab emtansine (T-DM1) versus paclitaxel plus trastuzumab to investigate if the two treatments had comparable efficacy and toxicity profile [88]. This evidence concerns the gene ERBB2 and breast cancer.